PriceTargets.com logo

Kezar Life Sciences - KZR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.50
  • Forecasted Upside: 430.91%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.85 As of 10/11/2024 01:00 AM ET
▼ -0.01 (-1.17%)

This chart shows the closing price for KZR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kezar Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KZR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KZR

Analyst Price Target is $4.50
▲ +430.91% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kezar Life Sciences in the last 3 months. The average price target is $4.50, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 430.91% upside from the last price of $0.85.

This chart shows the closing price for KZR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Kezar Life Sciences. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/2/2024HC WainwrightReiterated RatingBuy ➝ Neutral
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
7/22/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $7.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
12/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
11/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
11/14/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$4.00 ➝ $2.00
10/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
10/5/2023JonestradingReiterated RatingBuy ➝ Hold
9/25/2023HC WainwrightBoost TargetBuy ➝ Buy$18.00 ➝ $20.00
8/11/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $18.00
5/12/2023Wells Fargo & CompanyLower Target$14.00 ➝ $13.00
5/12/2023HC WainwrightLower Target$21.00 ➝ $19.00
3/16/2023HC WainwrightReiterated RatingBuy$21.00
3/15/2023William BlairReiterated RatingOutperform ➝ Market Perform
1/3/2023Wells Fargo & CompanyLower TargetOverweight$17.00 ➝ $14.00
8/12/2022HC WainwrightBoost TargetBuy$20.00 ➝ $21.00
6/28/2022JonestradingBoost Target$17.00 ➝ $20.00
6/28/2022Wells Fargo & CompanyBoost TargetOverweight$13.00 ➝ $17.00
5/4/2022Wells Fargo & CompanyLower Target$19.00 ➝ $14.00
4/22/2022Wells Fargo & CompanyReiterated RatingBuy$19.00
3/18/2022HC WainwrightBoost TargetBuy$20.00 ➝ $22.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$19.00
11/16/2021HC WainwrightBoost TargetPositive ➝ Buy$12.00 ➝ $20.00
8/30/2021HC WainwrightReiterated RatingBuy$12.00
7/20/2021JonestradingInitiated CoverageBuy$14.00
3/15/2021HC WainwrightReiterated RatingBuy$12.00
9/22/2020HC WainwrightReiterated RatingBuy$12.00
8/6/2020HC WainwrightReiterated RatingBuy$12.00
6/14/2020CowenReiterated RatingOutperform
6/14/2020Wells Fargo & CompanyReiterated RatingOverweight ➝ Market Perform$18.00
6/4/2020HC WainwrightReiterated RatingBuy$9.00 ➝ $12.00
5/5/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $9.00
3/13/2020William BlairReiterated RatingBuy
3/13/2020Wells Fargo & CompanyLower TargetOverweight$30.00 ➝ $18.00
11/6/2019CowenReiterated RatingBuy
10/21/2019HC WainwrightReiterated RatingBuy$15.00
(Data available from 10/12/2019 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/15/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/15/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/13/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/12/2024
  • 1 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/12/2024

Current Sentiment

  • 1 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Kezar Life Sciences logo
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.85
Low: $0.84
High: $0.87

50 Day Range

MA: $0.63
Low: $0.53
High: $0.86

52 Week Range

Now: $0.85
Low: $0.52
High: $1.14

Volume

240,065 shs

Average Volume

756,962 shs

Market Capitalization

$61.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Kezar Life Sciences?

The following Wall Street sell-side analysts have issued reports on Kezar Life Sciences in the last twelve months: HC Wainwright, and Wells Fargo & Company.
View the latest analyst ratings for KZR.

What is the current price target for Kezar Life Sciences?

2 Wall Street analysts have set twelve-month price targets for Kezar Life Sciences in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 430.9%. HC Wainwright has the highest price target set, predicting KZR will reach $7.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $2.00 for Kezar Life Sciences in the next year.
View the latest price targets for KZR.

What is the current consensus analyst rating for Kezar Life Sciences?

Kezar Life Sciences currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KZR, but not buy more shares or sell existing shares.
View the latest ratings for KZR.

What other companies compete with Kezar Life Sciences?

Other companies that are similar to Kezar Life Sciences include Hookipa Pharma, NextCure, Immutep, Poseida Therapeutics and Amarin. Learn More about companies similar to Kezar Life Sciences.

How do I contact Kezar Life Sciences' investor relations team?

Kezar Life Sciences' physical mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 822-5600 and its investor relations email address is [email protected]. The official website for Kezar Life Sciences is www.kezarlifesciences.com. Learn More about contacing Kezar Life Sciences investor relations.